Tourette Syndrome Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Tourette syndrome (TS) is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. Symptoms include eye blinking and other eye movements, facial grimacing, shoulder shrugging, and head or shoulder jerking. Other symptoms include touching the nose, smelling objects, flapping the arms, and hopping. The predisposing factors include age. Males are about three to four times more likely than females to develop Tourette syndrome. Treatment includes antidepressants, stimulant medications and behavior therapy.

The Tourette syndrome drugs in development report provides an overview of the Tourette syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Tourette Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Tourette Syndrome and features dormant and discontinued projects.

What are the targets of the Tourette syndrome pipeline drugs market?

The targets of the Tourette syndrome pipeline drugs market are Gamma-Aminobutyric Acid Type A Receptor Subunit (GABA, Alpha 1 Adrenergic Receptor, Beta 1 Adrenergic Receptor, cAMP and cAMP Inhibited Cgmp 3’, 5’ Cyclic Phosphodiesterase 10A, Cannabinoid Receptor 1, Cannabinoid Receptor 2, D1A Dopamine Receptor, D2 Dopamine Receptor, and Synaptic Vesicular Amine Transporter.

Tourette syndrome pipeline drugs market, by targets

For more target insights, download a free report sample

What are the mechanisms of action of the Tourette syndrome pipeline drugs market?

The mechanisms of action of the Tourette syndrome pipeline drugs market are Gamma-Aminobutyric Acid Type A Receptor Subunit (GABAAntagonist), Alpha 1 Adrenergic Receptor Antagonist, Beta 1 Adrenergic Receptor Antagonist, cAMP and cAMP Inhibited Cgmp 3’, 5’ Cyclic Phosphodiesterase 10A Inhibitor, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, D1A Dopamine Receptor Antagonist, D2 Dopamine Receptor Antagonist, and Synaptic Vesicular Amine Transporter Inhibitor.

Tourette syndrome pipeline drugs market, by mechanisms of action

For more mechanisms of action insights, download a free report sample

What are the routes of administration in the Tourette syndrome pipeline drugs market?

The routes of administration in the Tourette syndrome pipeline drugs market are oral, subcutaneous, and intravenous.

Tourette syndrome pipeline drugs market, by routes of administration

For more routes of administration insights, download a free report sample

What are the molecule types in the Tourette syndrome pipeline drugs market?

The molecule types in the Tourette syndrome pipeline drugs market are small molecule and antibody.

Tourette syndrome pipeline drugs market, by molecule types

For more molecule types insights, download a free report sample

Which are the key companies in the Tourette syndrome pipeline drugs market?

Some of the key companies in the Tourette syndrome pipeline drugs market are Asarina Pharma AB, Emalex Biosciences Inc, Evero Health Ltd, Noema Pharma AG, Octapharma AG, and SOM Biotech SL.

Tourette Syndrome pipeline drugs market, by key companies

To know more about key companies, download a free report sample

Market report scope

This report provides:

• A snapshot of the global therapeutic landscape of Tourette Syndrome (Central Nervous System).
• Reviews of pipeline therapeutics for Tourette Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
• Descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• Key companies involved in Tourette Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
• Evaluation of Tourette Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• All the dormant and discontinued pipeline projects.
• Reviews of the latest news related to pipeline therapeutics for Tourette Syndrome (Central Nervous System).

Reasons to Buy

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Tourette Syndrome (Central Nervous System).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Tourette Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understanding from the know-how what drove them from the pipeline.